The clinical efficacy of PD-1 inhibitor combined with lenvatinib in the treatment of primary liver cancer and its effects on the expression of serum VEGF and sVCAM1
LIU Yan,MA Shan,FU Zheng-zhuan
Department of Oncology, Zaozhuang Central Hospital, Shandong Guoxin Yiyang Group, Shandong Zaozhuang 277000, China
Abstract:
Objective To explore the clinical efficacy of PD-1 inhibitor combined with lenvatinib in the treatment of advanced primary liver cancer and its effects on the expression of serum vascular endothelial growth factor (VEGF) and soluble vascular cell adhesion molecule-1 (sVCAM1) in patients. Methods A total of 120 patients with advanced primary liver cancer who could not be operated in our hospital between April 2019 to April 2021 were selected and randomly divided into two groups, with 60 cases in each group. The observation group was treated with PD-1 inhibitors and combined with lenvatinib, and the control group was treated with lenvatinib alone. The short-term curative effect, serum VEGF and sVCAM1 expression levels, liver function and occurrence of adverse reactions were compared between the two groups. Results The total effective rate of treatment in the observation group 70.00% was significantly higher than that in the control group 48.33% (P<0.05). Before treatment, there was no statistical difference in the expression levels of VEGF [(225.47±45.09) (247.64±49.53)]ng/mL and sVCAM1 [(637.42±127.45) (712.55±142.51)]ng/mL, aspartate aminotransferase (AST) [(637.42±127.45) (712.55±142.51)]ng/mL, glutamate aminotransferase (ALT) [(40.57±8.11) (47.36±9.47)]U/L, serum total bilirubin (TBIL) [(10.38±2.08) (12.51±2.50)]μmol/L and alkaline phosphatase (ALP) [(64.57±12.91) (72.35±14.47)]U/L of the two groups (P>0.05); after treatment, the levels of VEGF and sVCAM1, AST, ALT, TBIL, and ALP decreased (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (21.67% vs 23.33%) (P>0.05). Conclusion PD-1 inhibitor combined with lenvatinib can significantly improve the treatment effect of patients with advanced primary liver cancer, improve liver function and immune function, etc., and have certain safety.
